Surmodics, Inc. (SRDX - Free Report) is a leading provider of medical device and in vitro diagnostic technologies to the health care industry that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on SRDX’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Surmodics could be a solid choice for investors.
Current Quarter Estimates for SRDX
In the past 30 days, one estimate has gone higher for Surmodics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates moving from a loss of 4 cents a share 30 days ago, to earnings of 10 cents today, a significant increase.
Current Year Estimates for SRDX
Meanwhile, Surmodics’ current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 5 cents per share 30 days ago to 20 cents per share today, also a significant increase.
The stock has also started to move higher lately, adding 13.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>